JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Home・Akciju saraksts・Simulations Plus Inc

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

13.99 -5.79

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

13.89

Max

14.68

Galvenie mērījumi
By Trading Economics
Ienākumi	3.9M 4.5M
Pārdošana	5.9M 24M
EPS	0.35
Dividenžu ienesīgums	0.48
Peļņas marža	18.669
Darbinieki	212
EBITDA	4.9M 7.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+14.37% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.48% 2.36%
Nākamie ieņēmumi	2026. g. 13. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	44M 295M
Iepriekšējā atvēršanas cena	19.78
Iepriekšējā slēgšanas cena	13.99

Ziņu noskaņojums

By Acuity

24%

76%

82 / 348 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. apr. 23:53 UTC

Peļņas

Naver Posts Weaker First-Quarter Earnings

2026. g. 29. apr. 23:41 UTC

Karstas akcijas

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

2026. g. 29. apr. 23:55 UTC

Peļņas

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 29. apr. 23:54 UTC

Peļņas

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

2026. g. 29. apr. 23:52 UTC

Peļņas

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

2026. g. 29. apr. 23:51 UTC

Peļņas

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

2026. g. 29. apr. 23:51 UTC

Tirgus saruna

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

2026. g. 29. apr. 23:34 UTC

Tirgus saruna

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

2026. g. 29. apr. 23:24 UTC

Peļņas

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

2026. g. 29. apr. 23:22 UTC

Peļņas

China Longyuan 1Q Net CNY1.70B, Down 14%

2026. g. 29. apr. 23:22 UTC

Peļņas

China Longyuan: Power Generation Down 2.9% as of End-March

2026. g. 29. apr. 23:20 UTC

Peļņas

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

2026. g. 29. apr. 23:20 UTC

Peļņas

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

2026. g. 29. apr. 23:19 UTC

Peļņas

China Vanke 1Q Loss Narrows>000002.SZ

2026. g. 29. apr. 23:18 UTC

Peļņas

Naver1Q Net Profit Missed FactSet-Compiled Consensus

2026. g. 29. apr. 23:17 UTC

Peļņas

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

2026. g. 29. apr. 23:15 UTC

Peļņas

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

2026. g. 29. apr. 23:15 UTC

Peļņas

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

2026. g. 29. apr. 23:13 UTC

Peļņas

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

2026. g. 29. apr. 23:12 UTC

Peļņas

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

2026. g. 29. apr. 23:11 UTC

Peļņas

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

2026. g. 29. apr. 23:11 UTC

Peļņas

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

2026. g. 29. apr. 23:04 UTC

Peļņas

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

2026. g. 29. apr. 23:04 UTC

Peļņas

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

14.37% augšup

Prognoze 12 mēnešiem

Vidējais 16 USD 14.37%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

82 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.